New imaging study peers inside tumors to see how immune drugs behave
NCT ID NCT05068102
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 32 times
Summary
This early-phase study uses special PET scans to see where two experimental drugs (BI 765063 and BI 770371) go in the body and how much they reach tumors. About 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments will receive one of these drugs along with another immune-boosting medicine called ezabenlimab. The main goal is to measure drug uptake in tumors, not to test effectiveness, so there is no direct treatment benefit expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VU University Medical Center
Amsterdam, 1081HV, Netherlands
Conditions
Explore the condition pages connected to this study.